Results 11 to 20 of about 4,166,507 (358)
mAbs, 2023 Excipients are added to biopharmaceutical formulations to enhance protein stability and enable the development of robust formulations with acceptable physicochemical properties, but the mechanism by which they confer stability is not fully understood ...
Chunting Zhang +11 more
doaj +1 more source
Toxicogenomics in Drug Development [PDF]
Toxicologic Pathology, 2003 Toxicogenomics represents the merging of toxicology with technologies that have been developed, together with bioinformatics, to identify and quantify global gene expression changes. It represents a new paradigm in drug development and risk assessment, which promises to generate a wealth of information towards an increased understanding of the ...
Jeanne Kehren +4 more
openaire +3 more sources
Developing Drugs For Developing Countries [PDF]
Health Affairs, 2006 Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S.
Jeffrey L. Moe +2 more
openaire +3 more sources
A brief overview of current drug repurposing approaches for COVID-19 management [PDF]
, 2020 This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares +1 more
core +2 more sources
The rule of five should not impede anti-parasitic drug development. [PDF]
, 2017 The "rule of 5" has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development.
Lipinski, Christopher A +1 more
core +1 more source
The development of antipsychotic drugs [PDF]
Brain and Neuroscience Advances, 2018 Antipsychotic drugs revolutionised psychiatric practice and provided a range of tools for exploring brain function in health and disease. Their development and introduction were largely empirical but based on long and honourable scientific credentials and remarkable powers of clinical observation.
Eve C. Johnstone, David G. C. Owens
openaire +3 more sources
Immuno-oncology combinations: raising the tail of the survival curve
Cancer Biology & Medicine, 2016 There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S.
Samuel J. Harris +3 more
doaj +1 more source
Patient-centric trials for therapeutic development in precision oncology [PDF]
, 2015 An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque +60 more
core +1 more source
Lipidomics in drug development [PDF]
Drug Discovery Today: Technologies, 2015 Numerous human pathologies, including common conditions such as obesity, diabetes, cardiovascular disease, cancer, inflammatory disease and neurodegeneration, involve changes in lipid metabolism. Likewise, a growing number of drugs are being developed that directly or indirectly affect lipid metabolic pathways.
Dehairs, Jonas +3 more
openaire +3 more sources
Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]
, 2014 Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L. +4 more
core +4 more sources